Tempus AI Reports Record Growth and Customer Engagement
Tempus AI, Inc. has shared preliminary, unaudited data showcasing a substantial revenue of approximately $316 million for the year 2025. This marks a 31% increase from the previous year, driven notably by a 38% growth in their Insight (data license) segment.
The net revenue retention rate for 2025 stands at around 126%, indicating strong ongoing relationships with existing customers even as the company expands its reach.
Based in Chicago, Tempus, listed under NASDAQ: TEM, announced a record Total Contract Value (TCV) exceeding $1.1 billion as of December 31, 2025. The company has secured data agreements with over 70 customers, spanning both large and midsize pharmaceutical entities such as AstraZeneca, GlaxoSmithKline, and Pfizer, among others. A notable number of biopharmaceutical companies, including Servier and Aspera Biomedicines, are now utilizing Tempus’ diverse datasets in their drug discovery efforts.
“The year 2025 has been unprecedented for our data and applications business, both in terms of revenue and TCV,” remarked Jim Rogers, Tempus’ Chief Financial Officer. He expressed confidence in the strong position of their data business, anticipating continued growth into 2026.
While Tempus is in the midst of finalizing its financials for the fourth quarter and the full year of 2025, the reported projections are subject to change as the company completes its statements. There’s an acknowledgment that final results might vary from these preliminary figures, which could be significant.
Tempus intends to disclose its complete financial results for both the fourth quarter and the entirety of 2025 during a conference call scheduled for February 2026.
About Tempus
Tempus is a technology-driven firm that seeks to enhance precision medicine using artificial intelligence in healthcare. With a vast multimodal data library, Tempus aims to equip physicians with innovative solutions that personalize patient care while improving the speed and efficacy of treatments. The goal? To leverage data from past patients to inform and optimize current healthcare decisions.
Forward-Looking Statements
This release contains forward-looking statements regarding Tempus, which involve potential risks and uncertainties. The statements primarily relate to preliminary financial results for the fourth quarter and full year of 2025, as well as expectations for 2026. Terms like “anticipate,” “believe,” and “estimate” may be indicative of forward-looking statements.
However, these projections should not be considered guarantees of future performance. They rely heavily on Tempus’ current perceptions and projections about trends and events that may influence its business environment. Risks range from financial performance concerns to challenges in attracting new clients and navigating the evolving regulatory landscape.
Key Indicators
Total Remaining Contract Value (TCV) reflects the full potential worth of signed contracts, while Net Revenue Retention examines annual revenue from consistent customers year-over-year.
